Medicine overview
Indications of Trimacontin
Trimacontin is indicated as add-on (adjunct) therapy for the symptomatic treatment of adult patients with stable angina pectoris who are inadequately controlled by, or are intolerant to, first-line antianginal therapies (such as beta-blockers or calcium channel blockers).
- Established/guideline-supported use: Symptomatic add-on treatment of chronic stable angina, used in combination with other antianginal agents.
- Not a monotherapy or rescue medication: Trimacontin is not intended for the initial treatment of unstable angina or myocardial infarction, and it does not relieve an acute anginal attack.
- Other reported/investigational uses: Trimacontin has been studied for adjunctive benefit in ischemic heart disease, heart failure symptoms, and Ménière's-type vertigo/tinnitus in some countries; these uses are not uniformly approved and should only be considered under a physician's guidance.
Full antianginal benefit is generally assessed after about three months of treatment; if no adequate response is seen, the physician may reconsider therapy.
Composition
Each tablet contains Trimetazidine Dihydrochloride as the active pharmaceutical ingredient, commonly available as:
- Immediate-release tablet: Trimetazidine Dihydrochloride 20 mg
- Modified-release (MR) tablet: Trimetazidine Dihydrochloride 35 mg
Tablets also contain standard pharmaceutical excipients (binders, fillers, coating agents) that vary by manufacturer.
Description
Trimacontin is a piperazine-derivative anti-anginal (anti-ischemic) agent that works through a metabolic mechanism rather than by altering heart rate or blood pressure. It is used as an add-on treatment for chronic stable angina in patients not adequately controlled on conventional antianginal drugs.
Unlike hemodynamic antianginal agents (beta-blockers, nitrates, calcium channel blockers), Trimacontin does not act on coronary blood flow or cardiac workload; instead it improves the heart muscle's tolerance to ischemia by optimizing its energy metabolism.
Therapeutic Class
Trimacontin belongs to the class of anti-anginal / anti-ischemic metabolic agents, distinct from beta-blockers, nitrates, and calcium channel blockers.
Pharmacology
Trimetazidine Dihydrochloride is a metabolic (cytoprotective) anti-ischemic agent. It inhibits the mitochondrial enzyme long-chain 3-ketoacyl-CoA thiolase (3-KAT), which partially shifts myocardial energy metabolism away from fatty-acid beta-oxidation toward glucose oxidation.
Because glucose oxidation requires less oxygen per unit of ATP generated than fatty-acid oxidation, this shift improves the efficiency of oxygen use by the ischemic myocardium, reduces intracellular acidosis and calcium overload, and helps maintain cellular energy homeostasis during ischemia.
Importantly, Trimetazidine Dihydrochloride has no significant hemodynamic effects — it does not significantly change heart rate, blood pressure, or coronary vascular tone, distinguishing its mechanism from that of conventional antianginal drugs.
Dosage & Administration of Trimacontin
Adult Dose (Stable Angina, add-on therapy)
| Formulation | Dose |
|---|---|
| Modified-release (MR) tablet 35 mg | One tablet twice daily, with meals (morning and evening) |
| Immediate-release tablet 20 mg | One tablet three times daily, with meals |
Renal Impairment
| Creatinine Clearance | Recommended Dose |
|---|---|
| 30–60 mL/min (moderate impairment) | 35 mg once daily (morning) or 20 mg twice daily |
| Below 30 mL/min (severe impairment) | Contraindicated — see Contraindications |
Elderly Patients
Elderly patients, particularly those with reduced renal function, should be dosed cautiously; the renal-impairment dosing schedule above should be applied if creatinine clearance is reduced.
Hepatic Impairment
No well-established dose adjustment has been defined for hepatic impairment; use with caution and physician supervision.
Duration and Monitoring
Antianginal benefit with Trimacontin should be reassessed after approximately three months of treatment; if no symptomatic improvement is observed, the physician should consider discontinuing therapy.
Administration of Trimacontin
Trimacontin tablets should be taken orally, with meals, swallowed whole with water. Modified-release tablets should not be crushed or chewed, as this may alter the controlled-release properties of the tablet.
Interaction of Trimacontin
Trimacontin has a low potential for clinically significant drug interactions and has not been reported to interact adversely with common cardiovascular medicines such as beta-blockers, calcium channel blockers, nitrates, heparin, digitalis (digoxin) preparations, or lipid-lowering agents, and it can generally be co-administered with these drugs.
As with any centrally-acting-symptom-associated medicine, caution is advised when Trimacontin is combined with drugs known to cause or worsen extrapyramidal/movement symptoms (e.g., certain antipsychotics, metoclopramide), because of the shared risk of parkinsonian symptoms — see Precautions and Warnings.
Contraindications
Trimetazidine Dihydrochloride is contraindicated in patients with:
- Known hypersensitivity to Trimetazidine Dihydrochloride or to any excipient of the formulation.
- Parkinson's disease, parkinsonian symptoms, tremor, restless legs syndrome, and other related movement disorders (current or history of).
- Severe renal impairment (creatinine clearance below 30 mL/min).
Side Effects of Trimacontin
Adverse effects reported with Trimacontin are usually mild and transient. Common effects include:
- Dizziness, headache
- Abdominal pain, nausea, vomiting, dyspepsia, diarrhea
- Rash, pruritus, urticaria
- Asthenia (generalized weakness)
Important (uncommon/rare) effects: Movement disorders — parkinsonian symptoms (tremor, rigidity, akinesia), gait instability, restless legs syndrome — have been reported, usually reversible after discontinuation (see Precautions and Warnings). Other rare effects include palpitations, extrasystoles, tachycardia, hypotension, and, very rarely, hepatic disorders and severe skin reactions (e.g., acute generalized exanthematous pustulosis).
Pregnancy & Lactation
Pregnancy: Data on use of Trimacontin during pregnancy are insufficient. As a precaution, it is preferable to avoid using Trimacontin during pregnancy. It should be used only if clearly needed and if the potential benefit to the mother justifies the potential risk to the fetus, and only after consulting a physician.
Lactation: It is not known whether Trimacontin or its metabolites are excreted in human breast milk. As a precaution, Trimacontin should not be used during breastfeeding; a physician should be consulted to weigh alternatives.
Precautions & Warnings
Movement disorders: Trimacontin may cause or worsen parkinsonian symptoms (tremor, akinesia, hypertonia), gait/balance disorders, restless legs syndrome, and other related movement disorders, particularly in elderly patients. Patients should be monitored regularly, especially early in treatment, and referred to a neurologist if symptoms occur. If such symptoms develop, Trimacontin should be discontinued; symptoms usually resolve within four months of stopping treatment. If parkinsonian symptoms persist beyond four months, neurological evaluation is required.
Not for acute attacks: Trimacontin has no established value in the initial treatment of unstable angina or myocardial infarction, and it does not provide relief for an acute anginal episode; it is intended solely as add-on background therapy.
Renal impairment: Dose should be reduced in moderate renal impairment and Trimacontin is contraindicated in severe renal impairment (see Dosage and Administration and Contraindications).
Falls risk: Because Trimacontin can cause dizziness and movement/balance disturbances, caution is advised in elderly patients and those at risk of falls, and in patients who drive or operate machinery until they know how the medicine affects them.
Overdose Effects of Trimacontin
Limited data exist on overdose with Trimacontin. In case of suspected overdose, symptoms may include exaggeration of known adverse effects. There is no specific antidote. Any suspected overdose should be treated as a medical emergency — seek immediate medical attention or contact a poison control center/emergency services promptly. Management is supportive and symptomatic, based on clinical assessment in a medical facility; do not attempt specific home treatment.
Storage Conditions
Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.
Use In Special Populations
Elderly
Elderly patients may be more susceptible to movement disorders and dizziness with Trimacontin; caution and renal-function-based dose adjustment are advised (see Dosage and Administration).
Renal Impairment
Dose reduction required in moderate renal impairment; contraindicated in severe renal impairment (creatinine clearance below 30 mL/min).
Hepatic Impairment
No well-established dosing data are available; use with caution under physician supervision.
Pediatric Population
Safety and efficacy of Trimacontin in children and adolescents have not been established; it is not recommended for use in this population.
Duration Of Treatment
Antianginal efficacy of Trimacontin should be evaluated after approximately three months of continuous treatment. If no satisfactory therapeutic response is observed by that time, the treating physician should reassess and consider discontinuing Trimacontin. Beyond this evaluation point, treatment duration is individualized by the prescribing physician based on ongoing symptom control.
Drug Classes
Anti-anginal agent; metabolic/anti-ischemic agent (piperazine derivative).
Mode Of Action
Trimetazidine Dihydrochloride selectively inhibits long-chain 3-ketoacyl-CoA thiolase (3-KAT), a key enzyme in mitochondrial fatty-acid beta-oxidation. By partially inhibiting fatty-acid oxidation, it shifts myocardial substrate utilization toward glucose oxidation, which requires less oxygen per ATP molecule produced. This improves the energy efficiency of ischemic cardiac cells, limits intracellular acidosis and ionic imbalance (sodium/calcium overload), and helps preserve cell membrane integrity during ischemia — without altering heart rate, blood pressure, or coronary blood flow.
Pediatric Uses
The safety and efficacy of Trimacontin in pediatric patients (below 18 years) have not been established. Trimacontin is therefore not recommended for use in children or adolescents.
Frequently Asked Questions
Q: What is Trimacontin 60 mg Tablet used for?
A: Trimacontin 60 mg Tablet is used as an add-on (adjunct) treatment for chronic stable angina in adults who are not adequately controlled by, or cannot tolerate, first-line antianginal medicines such as beta-blockers or calcium channel blockers. It is not used alone to treat an acute angina attack.
Q: Can Trimacontin 60 mg Tablet stop a sudden chest pain (angina) attack?
A: No. Trimacontin 60 mg Tablet is not a rescue medication and has no proven role in relieving an acute anginal attack or treating unstable angina or a heart attack. It works over time as background, add-on therapy alongside other antianginal medicines.
Q: Who should not take Trimacontin 60 mg Tablet?
A: Trimacontin 60 mg Tablet should not be used by people who are hypersensitive to it or its ingredients, people with Parkinson's disease or other movement disorders (such as tremor or restless legs syndrome), or people with severe kidney impairment. Always inform your physician of your full medical history before starting Trimacontin 60 mg Tablet.
Q: Does Trimacontin 60 mg Tablet cause any serious side effects?
A: Trimacontin 60 mg Tablet can, in some patients, cause or worsen movement disorders such as tremor, muscle stiffness, unsteady walking, or restless legs syndrome, resembling Parkinson's disease. These effects are usually reversible after stopping the medicine, but you should tell your doctor right away if they occur so that Trimacontin 60 mg Tablet can be discontinued and you can be evaluated.
Q: Is Trimacontin 60 mg Tablet safe during pregnancy or breastfeeding?
A: Data on the use of Trimacontin 60 mg Tablet during pregnancy are limited, so it is generally avoided in pregnancy and should only be used if a physician determines the benefit clearly outweighs the potential risk. It is also not recommended during breastfeeding, as it is not known whether it passes into breast milk. Always consult your physician before use in these situations.
Q: How should I take Trimacontin 60 mg Tablet, and what if I miss a dose or take too much?
A: Trimacontin 60 mg Tablet is typically taken with meals, either as a 35 mg modified-release tablet twice daily or a 20 mg tablet three times daily, exactly as prescribed by your physician. If you miss a dose, take it when you remember unless it is close to the next dose — do not double up. If an overdose is suspected, seek immediate medical attention or contact emergency/poison control services right away, as there is no specific antidote.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.
